![]() Ribavirin was not associated with higher SVR12 in GT3 compensated cirrhosis patients receiving SOF/VEL. However, addition of RBV did not significantly increase the SVR12 among treatment-experienced GT3 compensated cirrhosis patients. Subgroup analysis showed that RBV was associated with a higher SVR12 in GT3 compensated cirrhosis patients with baseline resistance-associated substitutions. Addition of RBV increased the pooled risk of treatment-related adverse events in GT3 compensated cirrhosis patients receiving SOF/VEL (RR: 4.20, 95%CI: 1.29-13.68 I 2 = 0%). The overall pooled rate of treatment-related adverse events was 7.2%. The SVR12 was similar in GT3 compensated cirrhosis patients, regardless of the use of RBV, for both the intention-to-treat RR 1.03, 95%CI: 0.99-1.07 I 2 = 0%) and the per-protocol analysis (RR: 1.03, 95%CI: 0.99-1.07 I 2 = 48%). The pooled relative risk (RR), 95%CI and heterogeneity ( I 2) were estimated using Review Manager version 5.3.įrom 1752 citations, a total of seven studies (2 randomized controlled trials, 5 cohort studies) with 1088 subjects were identified. The secondary outcome was treatment-related adverse events, as defined by symptomatic anemia requiring transfusion or a drop in hemoglobin beyond 2 g/dL. The primary outcome was sustained virological response 12-wk post-treatment (SVR12). All GT3 compensated cirrhosis patients treated with 12 wk of SOF/VEL, with or without RBV, were included, regardless of age, gender or prior treatment experience. There was no restriction on language, geography, publication dates and publication status (full text or abstracts). We searched four electronic databases (PubMed/Medline, Embase, Cochrane Library and Web of Science) from inception up to June 2021 using both free text and MeSH terms. To evaluate the efficacy and safety of SOF/VEL, with or without RBV in GT3 compensated cirrhosis patients. While the addition of ribavirin (RBV) to SOF/VEL improved sustained virological response (SVR12) in genotype 3 (GT3) decompensated cirrhosis patients, the benefits of RBV in GT3 compensated cirrhosis patients receiving SOF/VEL remains unclear. ![]() Sofosbuvir/velpatasvir (SOF/VEL) is an effective pan-genotypic direct-acting antiviral combination for treatment of chronic HCV infection. NTIRE 2019 Challenge on Real Image Super-Resolution: Methods and Results.Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and hepatocellular carcinoma globally. ![]() Khan, Fahad Shahbaz Khan, Ling Shao, Zhengping Wei, Lei Liu, Hong Cai, Darui Li, Fujie Gao, Zheng Hui, Xiumei Wang, Xinbo Gao, Guoan Cheng, Ai Matsune, Qiuyu Li, Leilei Zhu, Huaijuan Zang, Shu Zhan, Yajun Qiu, Ruxin Wang, Jiawei Li, Yongcheng Jing, Mingli Song, Pengju Liu, Kai Zhang, Jingdong Liu, Jiye Liu, Hongzhi Zhang, Wangmeng Zuo, Wenyi Tang, Jing Liu, Youngjung Kim, Changyeop Shin, Minbeom Kim, Sungho Kim, Pablo Navarrete Michelini, Hanwen Liu, Dan Zhu, Xuan Xu, Xin Li, Furui Bai, Xiaopeng Sun, Lin Zha, Yuanfei Huang, Wen Lu, Yanpeng Cao, Du Chen, Zewei He, Anshun Sun, Siliang Tang, Hongfei Fan, Xiang Li, Guo Li, Wenjie Zhang, Yumei Zhang, Qingwen He, Jinghui Qin, Lishan Huang, Yukai Shi, Pengxu Wei, Wushao Wen, Liang Lin, Jun Yu, Guochen Xie, Mengyan Li, Rong Chen, Xiaotong Luo, Chen Hong, Yanyun Qu, Cuihua Li, Zhi-Song Liu, Li-Wen Wang, Chu-Tak Li, Can Zhao, Bowen Li, Chung-Chi Tsai, Shang-Chih Chuang, Joonhee Choi, Joonsoo Kim, Xiaoyun Jiang, Ze Pan, Qunbo Lv, Zheng Tan, Peidong He: Jianrui Cai, Shuhang Gu, Radu Timofte, Lei Zhang, Xiao Liu, Yukang Ding, Dongliang He, Chao Li, Yi Fu, Shilei Wen, Ruicheng Feng, Jinjin Gu, Yu Qiao, Chao Dong, Dongwon Park, Se Young Chun, Sanghoon Yoon, Junhyung Kwak, Donghee Son, Syed Waqas Zamir, Aditya Arora, Salman H.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |